APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Inhalable Biologics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Respiratory Inhalable Biologics Market Outlook and Growth Opportunities 2026

8 January 2026191 pages

Choose your research edition.

Industry ResearchRespiratory Inhalable Biologics Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Inhalable Biologics Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Respiratory Inhalable Biologics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Inhalable Biologics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Inhalable Biologics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Respiratory Inhalable Biologics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Respiratory Inhalable Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Respiratory Inhalable Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Respiratory Inhalable Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Respiratory Inhalable Biologics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Respiratory Inhalable Biologics market include GSK, AstraZeneca, Boehringer Ingelheim, Vertex, Roche, Novartis, Chiesi, Teva and Prasco Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Respiratory Inhalable Biologics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Respiratory Inhalable Biologics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Respiratory Inhalable Biologics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Respiratory Inhalable Biologics market size, projected growth trends, production technologies, key applications, and end-use industries.

Respiratory Inhalable Biologics Segment by Company

GSK

AstraZeneca

Boehringer Ingelheim

Vertex

Roche

Novartis

Chiesi

Teva

Prasco Laboratories

Viatris

Amgen

Sumitomo Dainippon

Zhengdatianqing

Merck

Respiratory Inhalable Biologics Segment by Type

Protein Drugs

Peptide Drugs

Monoclonal Antibodies

Others

Respiratory Inhalable Biologics Segment by Application

Hospital

Retail Pharmacy

Others

Respiratory Inhalable Biologics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Respiratory Inhalable Biologics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Respiratory Inhalable Biologics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Respiratory Inhalable Biologics significant trends, drivers, influence factors in global and regions.

6. To analyze Respiratory Inhalable Biologics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Inhalable Biologics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Inhalable Biologics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Inhalable Biologics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Respiratory Inhalable Biologics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Respiratory Inhalable Biologics industry.

Chapter 3: Detailed analysis of Respiratory Inhalable Biologics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Respiratory Inhalable Biologics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Respiratory Inhalable Biologics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Respiratory Inhalable Biologics Industry Trends Table 2. Respiratory Inhalable Biologics Industry Drivers Table 3. Respiratory Inhalable Biologics Industry Opportunities and Challenges Table 4. Respiratory Inhalable Biologics Industry Restraints Table 5. Global Respiratory Inhalable Biologics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Respiratory Inhalable Biologics Revenue Share by Company (2021-2026) Table 7. Global Respiratory Inhalable Biologics Sales Volume by Company (k units ) & (2021-2026) Table 8. Global Respiratory Inhalable Biologics Sales Volume Share by Company (2021-2026) Table 9. Global Respiratory Inhalable Biologics Average Price (USD/unit) of Company (2021-2026) Table 10. Global Respiratory Inhalable Biologics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Respiratory Inhalable Biologics Key Company Manufacturing Base & Headquarters Table 12. Global Respiratory Inhalable Biologics Company, Product Type & Application Table 13. Global Respiratory Inhalable Biologics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Respiratory Inhalable Biologics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Protein Drugs Table 18. Significant Companies of Peptide Drugs Table 19. Significant Companies of Monoclonal Antibodies Table 20. Significant Companies of Others Table 21. Global Respiratory Inhalable Biologics Sales Volume by Type 2021 VS 2025 VS 2032 (k units ) Table 22. Global Respiratory Inhalable Biologics Sales Volume by Type (2021-2026) & (k units ) Table 23. Global Respiratory Inhalable Biologics Sales Volume by Type (2027-2032) & (k units ) Table 24. Global Respiratory Inhalable Biologics Sales Volume Share by Type (2021-2026) Table 25. Global Respiratory Inhalable Biologics Sales Volume Share by Type (2027-2032) Table 26. Global Respiratory Inhalable Biologics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Respiratory Inhalable Biologics Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Respiratory Inhalable Biologics Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Respiratory Inhalable Biologics Sales Value Share by Type (2021-2026) Table 30. Global Respiratory Inhalable Biologics Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Retail Pharmacy Table 33. Significant Companies of Others Table 34. Global Respiratory Inhalable Biologics Sales Volume by Application 2021 VS 2025 VS 2032 (k units ) Table 35. Global Respiratory Inhalable Biologics Sales Volume by Application (2021-2026) & (k units ) Table 36. Global Respiratory Inhalable Biologics Sales Volume by Application (2027-2032) & (k units ) Table 37. Global Respiratory Inhalable Biologics Sales Volume Share by Application (2021-2026) Table 38. Global Respiratory Inhalable Biologics Sales Volume Share by Application (2027-2032) Table 39. Global Respiratory Inhalable Biologics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Respiratory Inhalable Biologics Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Respiratory Inhalable Biologics Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Respiratory Inhalable Biologics Sales Value Share by Application (2021-2026) Table 43. Global Respiratory Inhalable Biologics Sales Value Share by Application (2027-2032) Table 44. Global Respiratory Inhalable Biologics Sales by Region: 2021 VS 2025 VS 2032 (k units ) Table 45. Global Respiratory Inhalable Biologics Sales by Region (2021-2026) & (k units ) Table 46. Global Respiratory Inhalable Biologics Sales Market Share by Region (2021-2026) Table 47. Global Respiratory Inhalable Biologics Sales by Region (2027-2032) & (k units ) Table 48. Global Respiratory Inhalable Biologics Sales Market Share by Region (2027-2032) Table 49. Global Respiratory Inhalable Biologics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Respiratory Inhalable Biologics Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Respiratory Inhalable Biologics Sales Value Share by Region (2021-2026) Table 52. Global Respiratory Inhalable Biologics Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Respiratory Inhalable Biologics Sales Value Share by Region (2027-2032) Table 54. Global Respiratory Inhalable Biologics Market Average Price (USD/unit) by Region (2021-2026) Table 55. Global Respiratory Inhalable Biologics Market Average Price (USD/unit) by Region (2027-2032) Table 56. Global Respiratory Inhalable Biologics Sales by Country: 2021 VS 2025 VS 2032 (k units ) Table 57. Global Respiratory Inhalable Biologics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Respiratory Inhalable Biologics Sales by Country (2021-2026) & (k units ) Table 59. Global Respiratory Inhalable Biologics Sales Market Share by Country (2021-2026) Table 60. Global Respiratory Inhalable Biologics Sales by Country (2027-2032) & (k units ) Table 61. Global Respiratory Inhalable Biologics Sales Market Share by Country (2027-2032) Table 62. Global Respiratory Inhalable Biologics Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Respiratory Inhalable Biologics Sales Value Market Share by Country (2021-2026) Table 64. Global Respiratory Inhalable Biologics Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Respiratory Inhalable Biologics Sales Value Market Share by Country (2027-2032) Table 66. GSK Company Information Table 67. GSK Business Overview Table 68. GSK Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 69. GSK Respiratory Inhalable Biologics Product Portfolio Table 70. GSK Recent Development Table 71. AstraZeneca Company Information Table 72. AstraZeneca Business Overview Table 73. AstraZeneca Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. AstraZeneca Respiratory Inhalable Biologics Product Portfolio Table 75. AstraZeneca Recent Development Table 76. Boehringer Ingelheim Company Information Table 77. Boehringer Ingelheim Business Overview Table 78. Boehringer Ingelheim Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. Boehringer Ingelheim Respiratory Inhalable Biologics Product Portfolio Table 80. Boehringer Ingelheim Recent Development Table 81. Vertex Company Information Table 82. Vertex Business Overview Table 83. Vertex Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Vertex Respiratory Inhalable Biologics Product Portfolio Table 85. Vertex Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Roche Respiratory Inhalable Biologics Product Portfolio Table 90. Roche Recent Development Table 91. Novartis Company Information Table 92. Novartis Business Overview Table 93. Novartis Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Novartis Respiratory Inhalable Biologics Product Portfolio Table 95. Novartis Recent Development Table 96. Chiesi Company Information Table 97. Chiesi Business Overview Table 98. Chiesi Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Chiesi Respiratory Inhalable Biologics Product Portfolio Table 100. Chiesi Recent Development Table 101. Teva Company Information Table 102. Teva Business Overview Table 103. Teva Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Teva Respiratory Inhalable Biologics Product Portfolio Table 105. Teva Recent Development Table 106. Prasco Laboratories Company Information Table 107. Prasco Laboratories Business Overview Table 108. Prasco Laboratories Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Prasco Laboratories Respiratory Inhalable Biologics Product Portfolio Table 110. Prasco Laboratories Recent Development Table 111. Viatris Company Information Table 112. Viatris Business Overview Table 113. Viatris Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Viatris Respiratory Inhalable Biologics Product Portfolio Table 115. Viatris Recent Development Table 116. Amgen Company Information Table 117. Amgen Business Overview Table 118. Amgen Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Amgen Respiratory Inhalable Biologics Product Portfolio Table 120. Amgen Recent Development Table 121. Sumitomo Dainippon Company Information Table 122. Sumitomo Dainippon Business Overview Table 123. Sumitomo Dainippon Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Sumitomo Dainippon Respiratory Inhalable Biologics Product Portfolio Table 125. Sumitomo Dainippon Recent Development Table 126. Zhengdatianqing Company Information Table 127. Zhengdatianqing Business Overview Table 128. Zhengdatianqing Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Zhengdatianqing Respiratory Inhalable Biologics Product Portfolio Table 130. Zhengdatianqing Recent Development Table 131. Merck Company Information Table 132. Merck Business Overview Table 133. Merck Respiratory Inhalable Biologics Sales (k units ), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Merck Respiratory Inhalable Biologics Product Portfolio Table 135. Merck Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Respiratory Inhalable Biologics Distributors List Table 139. Respiratory Inhalable Biologics Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Respiratory Inhalable Biologics Product Image Figure 2. Global Respiratory Inhalable Biologics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Inhalable Biologics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Respiratory Inhalable Biologics Sales (2021-2032) & (k units ) Figure 5. Global Respiratory Inhalable Biologics Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Respiratory Inhalable Biologics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Protein Drugs Image Figure 10. Peptide Drugs Image Figure 11. Monoclonal Antibodies Image Figure 12. Others Image Figure 13. Global Respiratory Inhalable Biologics Sales Volume by Type (2021 VS 2025 VS 2032) & (k units ) Figure 14. Global Respiratory Inhalable Biologics Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Respiratory Inhalable Biologics Sales Volume Share by Type (2021-2032) Figure 16. Global Respiratory Inhalable Biologics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Respiratory Inhalable Biologics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Respiratory Inhalable Biologics Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Retail Pharmacy Image Figure 21. Others Image Figure 22. Global Respiratory Inhalable Biologics Sales Volume by Application (2021 VS 2025 VS 2032) & (k units ) Figure 23. Global Respiratory Inhalable Biologics Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Respiratory Inhalable Biologics Sales Volume Share by Application (2021-2032) Figure 25. Global Respiratory Inhalable Biologics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Respiratory Inhalable Biologics Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Respiratory Inhalable Biologics Sales Value Share by Application (2021-2032) Figure 28. Global Respiratory Inhalable Biologics Sales by Region: 2021 VS 2025 VS 2032 (k units ) Figure 29. Global Respiratory Inhalable Biologics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Respiratory Inhalable Biologics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Respiratory Inhalable Biologics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Respiratory Inhalable Biologics Sales Value (2021-2032) & (US$ Million) Figure 33. North America Respiratory Inhalable Biologics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Respiratory Inhalable Biologics Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Respiratory Inhalable Biologics Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Respiratory Inhalable Biologics Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Respiratory Inhalable Biologics Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Respiratory Inhalable Biologics Sales Value (2021-2032) & (US$ Million) Figure 39. South America Respiratory Inhalable Biologics Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Respiratory Inhalable Biologics Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Respiratory Inhalable Biologics Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Respiratory Inhalable Biologics Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Respiratory Inhalable Biologics Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Protein Drugs
  • Peptide Drugs
  • Monoclonal Antibodies
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Others
Companies covered
  • GSK
  • AstraZeneca
  • Boehringer Ingelheim
  • Vertex
  • Roche
  • Novartis
  • Chiesi
  • Teva
  • Prasco Laboratories
  • Viatris
  • Amgen
  • Sumitomo Dainippon
  • Zhengdatianqing
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Respiratory Inhalable Biologics Sales Value (2021-2032)
  4. 1.2.2 Global Respiratory Inhalable Biologics Sales Volume (2021-2032)
  5. 1.2.3 Global Respiratory Inhalable Biologics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Respiratory Inhalable Biologics Market Dynamics
  1. 2.1 Respiratory Inhalable Biologics Industry Trends
  2. 2.2 Respiratory Inhalable Biologics Industry Drivers
  3. 2.3 Respiratory Inhalable Biologics Industry Opportunities and Challenges
  4. 2.4 Respiratory Inhalable Biologics Industry Restraints
3 Respiratory Inhalable Biologics Market by Company
  1. 3.1 Global Respiratory Inhalable Biologics Company Revenue Ranking in 2025
  2. 3.2 Global Respiratory Inhalable Biologics Revenue by Company (2021-2026)
  3. 3.3 Global Respiratory Inhalable Biologics Sales Volume by Company (2021-2026)
  4. 3.4 Global Respiratory Inhalable Biologics Average Price by Company (2021-2026)
  5. 3.5 Global Respiratory Inhalable Biologics Company Ranking (2024-2026)
  6. 3.6 Global Respiratory Inhalable Biologics Company Manufacturing Base and Headquarters
  7. 3.7 Global Respiratory Inhalable Biologics Company Product Type and Application
  8. 3.8 Global Respiratory Inhalable Biologics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Respiratory Inhalable Biologics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Respiratory Inhalable Biologics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Respiratory Inhalable Biologics Market by Type
  1. 4.1 Respiratory Inhalable Biologics Type Introduction
  2. 4.1.1 Protein Drugs
  3. 4.1.2 Peptide Drugs
  4. 4.1.3 Monoclonal Antibodies
  5. 4.1.4 Others
  6. 4.2 Global Respiratory Inhalable Biologics Sales Volume by Type
  7. 4.2.1 Global Respiratory Inhalable Biologics Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Respiratory Inhalable Biologics Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Respiratory Inhalable Biologics Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Respiratory Inhalable Biologics Sales Value by Type
  11. 4.3.1 Global Respiratory Inhalable Biologics Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Respiratory Inhalable Biologics Sales Value by Type (2021-2032)
  13. 4.3.3 Global Respiratory Inhalable Biologics Sales Value Share by Type (2021-2032)
5 Respiratory Inhalable Biologics Market by Application
  1. 5.1 Respiratory Inhalable Biologics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Others
  5. 5.2 Global Respiratory Inhalable Biologics Sales Volume by Application
  6. 5.2.1 Global Respiratory Inhalable Biologics Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Respiratory Inhalable Biologics Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Respiratory Inhalable Biologics Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Respiratory Inhalable Biologics Sales Value by Application
  10. 5.3.1 Global Respiratory Inhalable Biologics Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Respiratory Inhalable Biologics Sales Value by Application (2021-2032)
  12. 5.3.3 Global Respiratory Inhalable Biologics Sales Value Share by Application (2021-2032)
6 Respiratory Inhalable Biologics Regional Sales and Value Analysis
  1. 6.1 Global Respiratory Inhalable Biologics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Respiratory Inhalable Biologics Sales by Region (2021-2032)
  3. 6.2.1 Global Respiratory Inhalable Biologics Sales by Region: 2021-2026
  4. 6.2.2 Global Respiratory Inhalable Biologics Sales by Region (2027-2032)
  5. 6.3 Global Respiratory Inhalable Biologics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Respiratory Inhalable Biologics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Respiratory Inhalable Biologics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Respiratory Inhalable Biologics Sales Value by Region (2027-2032)
  9. 6.5 Global Respiratory Inhalable Biologics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Respiratory Inhalable Biologics Sales Value (2021-2032)
  12. 6.6.2 North America Respiratory Inhalable Biologics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Respiratory Inhalable Biologics Sales Value (2021-2032)
  15. 6.7.2 Europe Respiratory Inhalable Biologics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Respiratory Inhalable Biologics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Respiratory Inhalable Biologics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Respiratory Inhalable Biologics Sales Value (2021-2032)
  21. 6.9.2 South America Respiratory Inhalable Biologics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Respiratory Inhalable Biologics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Respiratory Inhalable Biologics Sales Value Share by Country, 2025 VS 2032
7 Respiratory Inhalable Biologics Country-level Sales and Value Analysis
  1. 7.1 Global Respiratory Inhalable Biologics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Respiratory Inhalable Biologics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Respiratory Inhalable Biologics Sales by Country (2021-2032)
  4. 7.3.1 Global Respiratory Inhalable Biologics Sales by Country (2021-2026)
  5. 7.3.2 Global Respiratory Inhalable Biologics Sales by Country (2027-2032)
  6. 7.4 Global Respiratory Inhalable Biologics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Respiratory Inhalable Biologics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Respiratory Inhalable Biologics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Respiratory Inhalable Biologics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Respiratory Inhalable Biologics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Respiratory Inhalable Biologics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Respiratory Inhalable Biologics Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Respiratory Inhalable Biologics Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Respiratory Inhalable Biologics Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Vertex
  20. 8.4.1 Vertex Company Information
  21. 8.4.2 Vertex Business Overview
  22. 8.4.3 Vertex Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Vertex Respiratory Inhalable Biologics Product Portfolio
  24. 8.4.5 Vertex Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Roche Respiratory Inhalable Biologics Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Respiratory Inhalable Biologics Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Chiesi
  38. 8.7.1 Chiesi Company Information
  39. 8.7.2 Chiesi Business Overview
  40. 8.7.3 Chiesi Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Chiesi Respiratory Inhalable Biologics Product Portfolio
  42. 8.7.5 Chiesi Recent Developments
  43. 8.8 Teva
  44. 8.8.1 Teva Company Information
  45. 8.8.2 Teva Business Overview
  46. 8.8.3 Teva Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Teva Respiratory Inhalable Biologics Product Portfolio
  48. 8.8.5 Teva Recent Developments
  49. 8.9 Prasco Laboratories
  50. 8.9.1 Prasco Laboratories Company Information
  51. 8.9.2 Prasco Laboratories Business Overview
  52. 8.9.3 Prasco Laboratories Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Prasco Laboratories Respiratory Inhalable Biologics Product Portfolio
  54. 8.9.5 Prasco Laboratories Recent Developments
  55. 8.10 Viatris
  56. 8.10.1 Viatris Company Information
  57. 8.10.2 Viatris Business Overview
  58. 8.10.3 Viatris Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Viatris Respiratory Inhalable Biologics Product Portfolio
  60. 8.10.5 Viatris Recent Developments
  61. 8.11 Amgen
  62. 8.11.1 Amgen Company Information
  63. 8.11.2 Amgen Business Overview
  64. 8.11.3 Amgen Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Respiratory Inhalable Biologics Product Portfolio
  66. 8.11.5 Amgen Recent Developments
  67. 8.12 Sumitomo Dainippon
  68. 8.12.1 Sumitomo Dainippon Company Information
  69. 8.12.2 Sumitomo Dainippon Business Overview
  70. 8.12.3 Sumitomo Dainippon Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Sumitomo Dainippon Respiratory Inhalable Biologics Product Portfolio
  72. 8.12.5 Sumitomo Dainippon Recent Developments
  73. 8.13 Zhengdatianqing
  74. 8.13.1 Zhengdatianqing Company Information
  75. 8.13.2 Zhengdatianqing Business Overview
  76. 8.13.3 Zhengdatianqing Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Zhengdatianqing Respiratory Inhalable Biologics Product Portfolio
  78. 8.13.5 Zhengdatianqing Recent Developments
  79. 8.14 Merck
  80. 8.14.1 Merck Company Information
  81. 8.14.2 Merck Business Overview
  82. 8.14.3 Merck Respiratory Inhalable Biologics Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Merck Respiratory Inhalable Biologics Product Portfolio
  84. 8.14.5 Merck Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Respiratory Inhalable Biologics Value Chain Analysis
  2. 9.1.1 Respiratory Inhalable Biologics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Respiratory Inhalable Biologics Sales Mode & Process
  6. 9.2 Respiratory Inhalable Biologics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Respiratory Inhalable Biologics Distributors
  9. 9.2.3 Respiratory Inhalable Biologics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst